Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns

Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's...